Compare Merck & Co., Inc. (MRK) vs Paychex, Inc. (PAYX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Paychex, Inc. — how do they compare? Merck & Co., Inc. trades at $144.97 (market cap $351.28B), while Paychex, Inc. trades at $104.54 (market cap $37.19B). The key difference: Merck & Co., Inc. is far larger — about 9.4× Paychex, Inc.'s market cap, and Paychex, Inc. pays the higher dividend (4.56%). Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Paychex, Inc. for 56 Days on average.
| MRK | PAYX | |
|---|---|---|
Market Cap | $351.28B | $37.19B |
Volume | 7,969,665 | 3,344,316 |
Sector | Health | Industrials |
52-Week High | $156.43 | $128.59 |
52-Week Low | $82.49 | $85.57 |
Typical Hold Time | 98 Days | 56 Days |
Enterprise Value | $398.04B | $40.87B |
Dividend Yield | 2.39% | 4.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.79, up 0.61% on the day, with a bearish technical signal despite beating earnings estimates in recent quarters. The company reported 2025 revenue of $65.01B and net income of $18.25B, with a high P/E ratio of 113.9 reflecting premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors have been increasing stakes.
The outlook is mixed: strong analyst consensus (68% buy ratings) and a $158.78 price target suggest upside, but high valuation and bearish technicals pose near-term risks. Key opportunities include pipeline expansion via M&A; risks involve integration challenges and patent pressures.
Paychex (PAYX) trades at $101.55, up 0.52% on the day, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 27.35% net income margin and 47.06% ROE, but valuation ratios like P/E of 20.73 and P/S of 5.67 appear elevated. Recent news highlights mixed sentiment, with earnings outperformance offset by concerns over dividend sustainability and labor market cooling.
The outlook is cautious; while fundamentals remain solid with consistent revenue growth, high debt levels and bearish technicals pose risks. Analyst consensus leans hold with a $111 price target, suggesting limited upside. Key opportunities include dividend yield and PEO growth, but investors face headwinds from economic sensitivity and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Paychex, Inc.
Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
Read more on PAYX →
